A nano-integrated diagnostic and therapeutic platform with oxidation-reduction reactions in tumor microenvironments

Nanoscale Adv. 2020 Mar 11;2(5):2192-2202. doi: 10.1039/c9na00786e. eCollection 2020 May 19.

Abstract

In the present study, we developed a nano-integrated diagnostic and therapeutic platform with oxidation-reduction reactions in tumor microenvironments (TMEs). The proposed platform resolved the contradiction of particle size between the enhanced permeability and retention (EPR) effect and tumor interstitial penetration, as well as poor circulation and low drug-loading efficiency. Flower-like MnO2 NPs were used as the core and modified with hyaluronate (HA) and H2PtCl6 to obtain MnO2-HA@H2PtCl6 (MHP). The maximum drug-loading efficiency rate of H2PtCl6 reached 35% due to its chelation with HA. MHP showed satisfactory integrity and stability during circulation and can also be used as a magnetic resonance imaging (MRI) contrast agent. In addition, MHP as a radiosensitizer achieved an excellent tumor inhibition effect in combination with radiotherapy. Importantly, MHP released ultra-small nanoparticles, USNPs, (∼20 nm) through the supramolecular self-assembly abilities of Mn2+, HA, and H2PtCl6 in TMEs, leading to the increase of penetration into multicellular spheres and solid tumors (Scheme), as well as prolonging its retention in tumors.